- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01319162
Prevalence of Polycystic Ovary Syndrome (PCOS) in Obese Premenopausal Women
To Estimate the Prevalence of PCOS in Obese Premenopausal Women and Elucidate How They Respond to a Weight Reduction Treatment Program
Between 40% and 85% of women with Polycystic Ovary Syndrome (PCOS) are overweight or obese and obesity is closely linked to the development of PCOS. Although it is well established that obesity increases the severity of the clinical features of PCOS, data regarding the prevalence of PCOS in obese women and the change in body weight in women with PCOS over time are scares. In a prevalence study it was investigated whether obesity increases the risk of PCOS in the general population and they demonstrated that the prevalence rate of PCOS in underweight, normal-weight, overweight, and obese women were 8.2, 9.8, 9.9, and 9.0%, respectively, similar to that observed in the general population. These results suggest that the risk of PCOS is only minimally increased with obesity. On the other hand, in a Spanish prevalence study among overweight and obese subjects, they demonstrated a 28.3% prevalence of PCOS, which is markedly higher compared with the 5.5% prevalence of PCOS in lean women in Spain.
First the investigators aim to estimate the prevalence/probability of PCOS among obese, premenopausal women (between 18 and 50 years) with no symptoms of classic menopausal symptoms in Sweden. Secondly, to elucidate whether women diagnosed with PCOS respond to standard weight reduction regime to the same extent as women without PCOS.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Göteborg, Szwecja, 41345
- Sahlgrenska Obesity Center at Sahlgrenska University hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
PCOS diagnostic criteria should be the presence of both clinical and/or biochemical hyperandrogenism and/or oligo-/amenorrhea and/or polycystic ovaries (PCO).
Exclusion Criteria:
- Exclusion of other endocrine disorders such as hyperprolactinemia (s-prolactin < 27µg/L), nonclassic congenital adrenal hyperplasia (17-hydroxyprogesterone < 3nmol/L), and androgen secreting tumors.
- Pregnancy or breastfeeding the last 6 months.
- Any sign of climacteric symptoms.
- Language barrier or disabled person with reduced ability to understand information.
- Oral contraceptives and insulin sensitizing agents is commonly used among women with PCOS since it may interfere with hormone profile. As the prevalence of PCOS can be assumed to be increased among women using oral contraceptives and insulin sensitizing agents, they are included but analyzed separately.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
---|---|
Women with PCOS
All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
|
The dietary intervention begins with a 12-weeks VLCD/LCD period.
The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal.
In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (<6 kcal/100 ml).
All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12.
At these visits general well-being and body weight will be monitored.
The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
|
Women without PCOS
All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
|
The dietary intervention begins with a 12-weeks VLCD/LCD period.
The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal.
In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (<6 kcal/100 ml).
All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12.
At these visits general well-being and body weight will be monitored.
The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Prevalence/probability of PCOS among obese, premenopausal women (between 18 and 50 years) with no symptoms of classic menopausal symptoms in Sweden.
Ramy czasowe: Within one month after first visit
|
Screening for PCOS among obese women includes menstrual history, clinical and biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound measure in women with one of signs included in the diagnosis of the syndrome.
|
Within one month after first visit
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Response to weight reduction regime among obese women with and without PCOS
Ramy czasowe: One year after inclusion
|
One year after inclusion
|
Food frequency
Ramy czasowe: Within one month after measure
|
Within one month after measure
|
Health Related Quality of Life
Ramy czasowe: Screening and one year later
|
Screening and one year later
|
Symptoms of anxiety and depression
Ramy czasowe: Screening and after one year
|
Screening and after one year
|
Changes in sex steroids and other related hormones
Ramy czasowe: Screening and after 1 year
|
Screening and after 1 year
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Publikacje ogólne
- Kataoka J, Larsson I, Lindgren E, Kindstrand LO, Schmidt J, Stener-Victorin E. Circulating Anti-Mullerian hormone in a cohort-study of women with severe obesity with and without polycystic ovary syndrome and the effect of a one-year weight loss intervention. Reprod Biol Endocrinol. 2022 Oct 29;20(1):153. doi: 10.1186/s12958-022-01022-0.
- Kataoka J, Larsson I, Bjorkman S, Eliasson B, Schmidt J, Stener-Victorin E. Prevalence of polycystic ovary syndrome in women with severe obesity - Effects of a structured weight loss programme. Clin Endocrinol (Oxf). 2019 Dec;91(6):750-758. doi: 10.1111/cen.14098. Epub 2019 Oct 1.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- Prevalence-PCOS-Obesity
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Zespół policystycznych jajników
-
Centre Hospitalier Universitaire DijonNovartis PharmaceuticalsRekrutacyjnyMegalencephaly-włośniczkowy zespół polimikrogyrii (MCAP)Francja
Badania kliniczne na Weight reduction regimen
-
University of North Carolina, Chapel HillWeight Watchers InternationalZakończonyNadwaga i otyłośćStany Zjednoczone
-
Zimmer BiometWycofaneZwyrodnieniowa choroba dyskuStany Zjednoczone
-
Medical University of South CarolinaWeight Watchers InternationalZakończonyOtyłość | Nadwaga | Cukrzyca typu 2Stany Zjednoczone
-
University of PennsylvaniaWeight Watchers InternationalZakończony
-
University Hospital, GhentZakończony
-
University of British ColumbiaZakończonyNadwaga i otyłość | Dieta KetogenicznaKanada
-
The Miriam HospitalUniversity of Tennessee; Weight Watchers InternationalZakończony
-
Northwestern UniversityZakończonyTrądzikStany Zjednoczone
-
Walter Reed Army Medical CenterZakończony
-
The Miriam HospitalZakończony